Format
Items per page
Sort by

Send to:

Choose Destination

Results: 14

Related Articles by Review for PubMed (Select 22713701)

1.

UGT1A4*3 encodes significantly increased glucuronidation of olanzapine in patients on maintenance treatment and in recombinant systems.

Haslemo T, Loryan I, Ueda N, Mannheimer B, Bertilsson L, Ingelman-Sundberg M, Molden E, Eliasson E.

Clin Pharmacol Ther. 2012 Aug;92(2):221-7. doi: 10.1038/clpt.2012.46. Epub 2012 Jun 20.

PMID:
22713701
2.

Olanzapine: in adolescents with schizophrenia or bipolar I disorder.

McCormack PL.

CNS Drugs. 2010 May;24(5):443-52. doi: 10.2165/11204430-000000000-00000. Review.

PMID:
20369908
3.

[Antipsychotics in bipolar disorders].

Vacheron-Trystram MN, Braitman A, Cheref S, Auffray L.

Encephale. 2004 Sep-Oct;30(5):417-24. Review. French.

PMID:
15627046
4.

Olanzapine: a 5-year perspective.

Littrell KH, Petty RG, Wolf NM.

Expert Rev Neurother. 2006 Jun;6(6):811-21. Review.

PMID:
16784405
5.

Does olanzapine warrant clinical pharmacokinetic monitoring in schizophrenia?

Schwenger E, Dumontet J, Ensom MH.

Clin Pharmacokinet. 2011 Jul;50(7):415-28. doi: 10.2165/11587240-000000000-00000. Review.

PMID:
21651311
6.

[Economic analyses of olanzapine in the treatment of schizophrenia and bipolar disorder].

Dilla T, Prieto L, Ciudad A, Sacristán JA.

Actas Esp Psiquiatr. 2004 Sep-Oct;32(5):269-79. Review. Spanish.

PMID:
15529211
7.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
8.
9.

Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder.

Citrome L, Holt RI, Walker DJ, Hoffmann VP.

Clin Drug Investig. 2011;31(7):455-82. doi: 10.2165/11589060-000000000-00000. Review.

PMID:
21495734
10.

Pharmacogenetics of olanzapine metabolism.

Söderberg MM, Dahl ML.

Pharmacogenomics. 2013 Aug;14(11):1319-36. doi: 10.2217/pgs.13.120. Review.

PMID:
23930678
11.

N-glucuronidation of drugs and other xenobiotics by human and animal UDP-glucuronosyltransferases.

Kaivosaari S, Finel M, Koskinen M.

Xenobiotica. 2011 Aug;41(8):652-69. doi: 10.3109/00498254.2011.563327. Epub 2011 Mar 24. Review.

PMID:
21434773
12.

Olanzapine. Pharmacokinetic and pharmacodynamic profile.

Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM.

Clin Pharmacokinet. 1999 Sep;37(3):177-93. Review.

PMID:
10511917
13.

[Olanzapine].

Wittköpper K, El-Armouche A, Eschenhagen T.

Dtsch Med Wochenschr. 2008 Sep;133(39):1958-62. doi: 10.1055/s-0028-1085603. Epub 2008 Sep 16. Review. German. No abstract available.

PMID:
18798132
14.

Olanzapine: an updated review of its use in the management of schizophrenia.

Bhana N, Foster RH, Olney R, Plosker GL.

Drugs. 2001;61(1):111-61. Review.

PMID:
11217867
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk